Skip to main content

Table 1 Patient characteristics

From: Budesonide inhalation suspension versus methylprednisolone for treatment of moderate bronchial asthma attacks

 

mPSL group

BIS group

p

(n = 20)

(n = 20)

Age (years)

3.1 ± 1.4

3.1 ± 1.3

n.s.

Sex

Male: 14

Male: 13

n.s.

Female: 6

Female: 7

Cases of atopic asthma

14

14

n.s.

Mite-specific IgE (UA/mL)

6.3 ± 21.0

8.9 ± 22.7

n.s.

Regular treatment for asthma prior to admission

None: 5

None: 6

n.s.

Montelkast or Pranlukast: 15

Montelkast or Pranlukast: 14

Inhaled corticosteroids: 10

Inhaled corticosteroids: 6

Passive smoking

5

6

n.s.

Pet-keeping

4

2

n.s.

  1. JPGL2008, Japanese pediatric guideline for the treatment and management of asthma 2008; mPSL, methylprednisolone; BIS, budesonide inhalation suspension; ECP, eosinophil cationic protein; n.s., not significant.